share_log

中國中藥：2024年6月14日舉行之股東週年大會之投票表決結果

TRAD CHI MED: POLL RESULTS OF ANNUAL GENERAL MEETINGHELD ON 14 JUNE 2024

Hong Kong Stock Exchange ·  Jun 14 19:17
Summary by Futu AI
中國中藥控股有限公司（「中國中藥」）於2024年6月14日召開股東週年大會，會上所有提出的決議案均獲得股東投票通過。這些決議包括審核並通過了截至2023年12月31日止年度的財務報表、董事會報告及獨立核數師報告，以及重選多名董事和授權董事會釐定董事酬金。此外，安永會計師事務所也被重聘為公司核數師，並授權董事會釐定其酬金。股東週年大會上出席的董事包括執行董事陳映龍先生，非執行董事程學仁先生，以及獨立非執行董事謝榮先生、余梓山先生、秦嶺先生及李偉東先生。香港中央證券登記有限公司作為監票員，負責處理點票事宜。截至大會日期，公司已發行股份總數為5,035,801,852股。
中國中藥控股有限公司（「中國中藥」）於2024年6月14日召開股東週年大會，會上所有提出的決議案均獲得股東投票通過。這些決議包括審核並通過了截至2023年12月31日止年度的財務報表、董事會報告及獨立核數師報告，以及重選多名董事和授權董事會釐定董事酬金。此外，安永會計師事務所也被重聘為公司核數師，並授權董事會釐定其酬金。股東週年大會上出席的董事包括執行董事陳映龍先生，非執行董事程學仁先生，以及獨立非執行董事謝榮先生、余梓山先生、秦嶺先生及李偉東先生。香港中央證券登記有限公司作為監票員，負責處理點票事宜。截至大會日期，公司已發行股份總數為5,035,801,852股。
China Traditional Chinese Medicine Holdings Co., Ltd. ("trad chi med") held its annual general meeting of shareholders on June 14, 2024, and all proposed resolutions were passed by the shareholders. These resolutions include the review and approval of the financial statements, board of directors' report and independent auditor's report for the year ended December 31, 2023, as well as the re-election of multiple directors, and authorization of the board of directors to determine director's remuneration. In addition, Ernst & Young was reappointed as the company's auditor and authorized the board of directors to determine its compensation. The directors present at the annual general meeting included Executive Director Mr. Chen Yinglong, Non-executive Director Mr. Cheng Xueren, and Independent Non-executive Directors Mr. Xie Rong, Mr. Yu Zishan, Mr. Qin Ling and Mr. Li Weidong. Hong Kong Central Clearing and Settlement Company Limited served as the scrutineer and was responsible for counting the votes. As of the date of the meeting, the total number of issued shares of the company was 5,035,801,852 shares.
China Traditional Chinese Medicine Holdings Co., Ltd. ("trad chi med") held its annual general meeting of shareholders on June 14, 2024, and all proposed resolutions were passed by the shareholders. These resolutions include the review and approval of the financial statements, board of directors' report and independent auditor's report for the year ended December 31, 2023, as well as the re-election of multiple directors, and authorization of the board of directors to determine director's remuneration. In addition, Ernst & Young was reappointed as the company's auditor and authorized the board of directors to determine its compensation. The directors present at the annual general meeting included Executive Director Mr. Chen Yinglong, Non-executive Director Mr. Cheng Xueren, and Independent Non-executive Directors Mr. Xie Rong, Mr. Yu Zishan, Mr. Qin Ling and Mr. Li Weidong. Hong Kong Central Clearing and Settlement Company Limited served as the scrutineer and was responsible for counting the votes. As of the date of the meeting, the total number of issued shares of the company was 5,035,801,852 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.